Oct 26, 2020
Rahul Aras, CEO, Iterion Therapeutics, describes their lead product Tegavivint, a potent selective inhibitor of nuclear beta-catenin, a high-value oncology target because of its role in cell proliferation, differentiation, immune evasion and other aspects of cancer development. An early clinical study in patients with the rare disease Desmoid tumors has showed that their tumor stabilized and reversed in size. Progress is being driven by recent understanding of the role of TBL1 in driving oncogenic activity of beta-catenin.
#IterionTherapeutics #Tegavivint #cancer #DesmoidTumors #nuclearbetacatenin #TBL1